IngentaConnect Spotlight on Eletriptan in Migraine

Authors: McCormack, Paul L.¹; Keating, Gillian M.¹

Source: CNS Drugs, Volume 20, Number 11, 2006 , pp. 961-964(4)

Abstract:

Eletriptan (Relpax^®) is an orally administered, lipophilic, highly selective serotonin 5-HT_1B/1D receptor agonist (`triptan') that is effective in the acute treatment of moderate to severe migraine attacks in adults. It has a rapid onset of action and demonstrates superiority over placebo as early as 30 minutes after the administration of a single 40 or 80mg oral dose. The efficacy of eletriptan 20mg was similar to that of sumatriptan 100mg, while eletriptan 40 and 80mg displayed greater efficacy than sumatriptan 50 or 100mg for most endpoints. Eletriptan 40mg was generally superior to naratriptan 2.5mg and equivalent to almotriptan 12.5mg, rizatriptan 10mg and zolmitriptan 2.5mg, while eletriptan 80mg was superior to zolmitriptan 2.5mg for most efficacy parameters. Eletriptan 40 and 80mg were consistently superior to ergotamine/caffeine. Eletriptan is generally well tolerated, reduces time lost from normal activities, improves patients' health-related quality of life and appears to be at least as, if not more, cost effective than sumatriptan. Eletriptan is therefore a useful addition to the triptan family and a first-line treatment option in the acute management of migraine attacks.

Keywords: Adis Spotlights; Antimigraines; Eletriptan; Eletriptan; Eletriptan; Eletriptan; Migraine; Serotonin receptor agonists

Document Type: Research article

Affiliations: 1: Wolters Kluwer Health | Adis, Auckland, New Zealand, an editorial office of Wolters Kluwer Health, Conshohocken, Pennsylvania, USA

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$57.95 plus tax Refund Policy